| First Author | Fisher DAC | Year | 2023 |
| Journal | Exp Hematol | PubMed ID | 37611729 |
| Mgi Jnum | J:342495 | Mgi Id | MGI:7538688 |
| Doi | 10.1016/j.exphem.2023.08.005 | Citation | Fisher DAC, et al. (2023) Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice. Exp Hematol |
| abstractText | Hyperactivation of JAK2 kinase is a unifying feature of human Ph- myeloproliferative neoplasms (MPNs), most commonly due to the JAK2 V617F mutation. Mice harboring a homologous mutation in the Jak2 locus exhibit a phenotype resembling polycythemia vera. NFkappaB pathway hyperactivation is present in myeloid neoplasms, including MPNs, despite scarcity of mutations in NFkappaB pathway genes. To determine the impact of NFkappaB pathway hyperactivation in conjunction with Jak2 V617F, we utilized Ikk2 (Ikk2-CA) mice. Pan-hematopoietic Ikk2-CA alone produced depletion of hematopoietic stem cells and B cells. When combined with the Jak2 V617F mutation, Ikk2-CA rescued the polycythemia vera phenotype of Jak2 V617F. Likewise, Jak2 V617F ameliorated defects in hematopoiesis produced by Ikk2-CA. Single-cell RNA sequencing of hematopoietic stem and progenitor cells revealed multiple genes antagonistically regulated by Jak2 and Ikk2, including subsets whose expression was altered by Jak2 V617F and/or Ikk2-CA but partly or fully rectified in the double mutant. We hypothesize that Jak2 promotes hematopoietic stem cell population self-renewal, whereas Ikk2 promotes myeloid lineage differentiation, and biases cell fates at several branch points in hematopoiesis. Jak2 and Ikk2 both regulate multiple genes affecting myeloid maturation and cell death. Therefore, the presence of dual Jak2 and NFkappaB hyperactivation may present neomorphic therapeutic vulnerabilities in myeloid neoplasms. |
